|
|
- 2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b studyDOI: 10.1016/j.trci.2016.12.003 Keywords: Alzheimer's disease, CAD106, Active immunotherapy, Amyloid-beta peptides, Safety, Biological biomarkers Abstract: This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without adjuvant in patients with mild Alzheimer's disease
|
